Cognitive Changes in Alzheimer's Disease Patients Associated With or Without White Matter Changes After Rivastigmine

• Status: Completed
• Trial end date: 2017-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate and compare the changes of cognitive function (as measured by ADAS-Cog) in the two group of patients with Alzheimer's disease (AD) associated with and without white matter changes after rivastigmine patch therapy.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dong-A University
• Collaborator: Novartis Korea Ltd.
• Treatments: Rivastigmine

Criteria

Inclusion Criteria:

• AD in NINCDS-ADRDA criteria, mild to moderate

• probable AD with or without mild to moderate whiter matter lesions, excluding multiple large vessel infarcts or a single, strategically placed infarct (angular gyrus, thalamus, basal forebrain, territory of the posterior or anterior cerebral artery) on MRI scan (within 12 months)

• MMSE score : 10 to 26 at screening

• Hachinski scores ≤ 4

• No clinically significant laboratory abnormalities, such as thyroid disease, vitamine B12 deficiency or folic acid deficiency

Exclusion Criteria:

• Current evidence of history of neurological, psychiatric and other illness that could contribute to dementia

• Subjects with clinical significant cardiovascular disease, stroke, pulmonary disease or any other medical disease in the past 6 months

• History of cancer within the last 5 years

• Subjects with evidence or history of clinically significant allergic reaction to AchEI or drugs

• Subjects who had significant visual or hearing difficulties